First results of randomised clinical screening trials are traditionally met with a barrage of comments by opinionated observers, and the back-to-back publication in the March 26 issue of the New England Journal of Medicine on [more]
Suppressing metastases by changing microenvironments doesn’t sound like heartland research for a surgeon. But that hasn’t deterred Michael Gnant, who presented a paper on this subject at last year’s ASCO. He argues that cancer surgery [more]
The treatment of ovarian cancer and management of advanced ovarian cancer have progressed over the past few decades through several key milestones, including improvements in surgery, the evolution of chemotherapy and the establishment of an [more]
Too slow, too expensive, too ineffective. Researchers are crying out for a new battle plan that will aim high and deliver on the great promise of personalised therapies. We all want to see target patient [more]
Mario Dicato is one of a dwindling band of academic haemato-medical oncologists, who has relished a career jumping from one topic to the next as opportunities arise. Whether treating patients with confiscated marijuana, developing the [more]
Preclinical studies have shown that, in addition to showing anti-multiple-myeloma activity as single agents, new agents such as bortezomib also enhance the efficacy of chemotherapy and steroids. A randomised trial has now established that bortezomib [more]
Selected reports edited by Janet Fricker Download full article
The EUROCARE 4 report has delivered an implicit merit mark to eastern European countries, whose relatively poor survival figures are now improving faster than those in the rest of Europe. But older patients are still [more]
Hopes that angiogenesis inhibition could improve outcomes when used adjuvantly in colorectal cancer received a setback at the end of April, with the announcement that the NSABP C-08 trial had failed to meet its primary [more]